Globus Medical's post-NuVasive integration has driven a remarkable margin transformation, with gross margin expanding from 59.9% in Q4 2024 to 69.4% in Q2 2026 and operating margin rising from 9.2% to 23.1% over the same period. The balance sheet is fortress-l...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 27% in Q1 2026 but slowed to 5.9% in Q2 2026, while gross margin expanded to 69.4% and operating margin reached 23.1%, reflecting strong operational leverage.
Record Q4 and full year 2025 results, along with raised non-GAAP EPS guidance, indicate robust financial health.
Management reaffirmed 2026 revenue guidance of US$3.18 billion to US$3.22 billion, signaling confidence in future growth.
Operating in the Medical Devices sector, Globus Medical is well-positioned in a high-growth industry.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.34+21.8% vs $1.10 | $790M+0.9% vs $783M |
Q2 2026 May 7, 2026 | $1.12+21.7% vs $0.92 | $760M+2.6% vs $740M |
Q1 2026 Feb 24, 2026 | $1.28+20.8% vs $1.06 | $826M+3.1% vs $802M |
Q4 2025 Nov 6, 2025 | $1.18+51.1% vs $0.78 | $769M+4.7% vs $735M |
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Robotics is poised for robust long-term growth. Consider NVDA, TER, ZBRA and GMED for potential market dominance across sectors.
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Integer (ITGR). But which of these two companies is the best option for those looking for undervalued stocks?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Benchmark GMED against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Globus Medical, Inc. (GMED)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $75.19 | $10.14B | 19.18 | 16.65% | 18.3% | 12.29% | — | |
| $275.07 | $105.45B | 32.75 | 11.16% | 14.43% | 16.36% | — | |
| $93.98 | $18.18B | 26.47 | 7.2% | 9.48% | 6.36% | — | |
| $10.33 | $1.59B | -10.76 | 24.95% | -13.5% | -818.99% | — | |
| $0.36 | $50.49M | 12.00 | 14.21% | -10.17% | -23.45% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — |
Globus Medical, Inc. (GMED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Globus Medical, Inc. (GMED) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 4, 2026·SEC
May 7, 2026·SEC
Get notified when GMED posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Globus Medical, Inc. (GMED) stock FAQ — growth, dividends, profitability & financials explained
Globus Medical, Inc. (GMED) reported $3.14B in revenue for fiscal year 2025. This represents a 991% increase from $288.2M in 2010.
Globus Medical, Inc. (GMED) grew revenue by 16.7% over the past year. This is strong growth.
Yes, Globus Medical, Inc. (GMED) is profitable, generating $535.5M in net income for fiscal year 2025 (18.3% net margin).
Globus Medical, Inc. (GMED) has a return on equity (ROE) of 12.3%. This is reasonable for most industries.
Globus Medical, Inc. (GMED) generated $750.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
